News of Note—GlaxoSmithKline in Nigeria; Mexico fights shortages

Financial market data. Image: Pixabay
(Pixabay)

> GlaxoSmithKline Consumer Nigeria has selected Nigeria's Fidson Healthcare to manufacture five formations of its respiratory and wellness products for the Nigerian market. Story

> Lupin has received a notice from the FDA that an inspection of its plant in Goa resulted in a finding of Official Action Indicated. Story

> The Mexican government has pledged to fix drug shortages at hospitals that have been blamed on a government plan aimed at cutting costs. Story

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

> The FDA's Office of Pharmaceutical Quality has issued a report on strides made to improve the global drug supply that comes into the U.S. Report (PDF)

> Fujifilm Diosynth Biotechnologies is investing £3.6 million to build a new facility at its site in the U.K., the first phase of a £12.6 million expansion project. Story

> According to a new report from CPhI, the Middle East currently imports about 90% of its medicines and is ripe for expansion for local manufacturing. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.